Medscape1h
‘Take a Photograph’: Trial Shows Big Survival Gain in Advanced EGFR-Mutant NSCLC
Final overall survival results show amivantamab plus lazertinib beat out osimertinib for first-line treatment of advanced ...
Clinical Trials Arena on MSN21h
J&J’s NSCLC combo projected to extend survival by one year over Tagrisso
Rybrevant (amivantamab-vmjw) and Lazcluze (lazertinib) combination therapy is projected to increase overall survival (OS) by ...
Medscape1d
Surgical Delay Linked to Higher Mortality Risk in HR+/HER2− Breast Cancer
Researchers conducted a retrospective cohort study of 34,248 women diagnosed with locoregional breast cancer who received ...
J&J says Rybrevant/Lazcluze outperforms osimertinib OS in Phase 3 study
Johnson & Johnson announced results for the “gold standard endpoint in cancer treatment” of overall survival from the Phase 3 ...
HealthDay on MSN2d
Molecular Residual Disease Analysis May Predict Disease Recurrence After Lung Cancer Resection
For patients with resected stage IB-IIIA epidermal growth factor receptor-mutated non-small cell lung cancer, molecular ...
Clinical Trials Arena on MSN3d
Innovent Biologics doses first subject in trial of ovarian cancer therapy
Innovent Biologics has dosed the first subject in the randomised Phase III HeriCare-Ovarian01 trial of IBI354 for treating ...
AstraZeneca announces results presented at ELCC on Tagrisso
New study results presented at the European Lung Cancer Congress, ELCC, 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s (AZN) ...
Science Daily8d
Vaccine may improve breast cancer treatment outcomes
Researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor 2-positive, estrogen ...